Trial intelligence / Profile preview

Linperlisib + Chidamide in R/R PTCL

NCT07139353Phase 2

Key facts

Status: Not yet recruiting
Start: Sep 2025
Primary completion: Sep 2027
Sponsor: Sun Yat-sen University
Modality: Small Molecules

Drugs: linperlisib
Conditions: peripheral T-cell lymphoma (PTCL)

Overview

Phase 2, open-label, single-arm trial of linperlisib in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University. Primary endpoints: Dose-limiting toxicity at 28 days and Overall Response Rate at 24 months. Planned start Sep 2025; status: not yet recruiting.

Design

1 arm

Study design: Non-randomizedOpen-label

Linperlisib + Chidamide
Linperlisib combined with Chidamide

Who it enrols

Patients with relapsed or refractory PTCL who have failed at least one prior line of systemic therapy, with adequate organ function and no active infections or CNS involvement.

Endpoints

Primary

Dose-limiting toxicity28 days
Overall Response Rate24 months

Secondary

Complete Response Rate24 months
Duration of Response4 years
Progression-Free Survival4 years
Overall Survival4 years

Beyond the preview

Go deeper on NCT07139353.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07139353.